Genmab A/S said that, based on discussions with regulators, it has sufficient data to file a marketing authorisation application in Europe for zalutumumab for the second-line treatment of patients with head and neck cancer. ---Subscribe to MedNous to access this article--- Company News Regulation & Policy
